AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes

c-Src is frequently activated in human malignancies, including colon, breast, and pancreatic carcinomas. Several recent studies have shown that activation of Src family kinases leads to tumor progression and metastasis by increasing cellular migration and invasion, promoting cell growth and survival...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2005-12, Vol.4 (12), p.1900-1911
Hauptverfasser:	Summy, Justin M, Trevino, Jose G, Lesslie, Donald P, Baker, Cheryl H, Shakespeare, William C, Wang, Yihan, Sundaramoorthi, Raji, Metcalf, 3rd, Chester A, Keats, Jeffrey A, Sawyer, Tomi K, Gallick, Gary E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Triphosphate - analogs & derivatives Adenosine Triphosphate - pharmacology Animals Base Sequence Blotting, Western Cell Line, Tumor Cell Movement DNA Primers Endothelium, Vascular - cytology Endothelium, Vascular - drug effects Endothelium, Vascular - metabolism Enzyme Inhibitors - pharmacology Enzyme-Linked Immunosorbent Assay Humans IL-8 Immunoprecipitation Interleukin-8 - metabolism Mice Mice, Inbred C3H Neoplasms - blood supply Neoplasms - metabolism Neovascularization, Pathologic - prevention & control pancreatic cancer Phosphorylation RNA, Small Interfering Src family kinase src-Family Kinases - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism VEGF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!